Our pipeline
| Development status | |||||||
| Programme | Product | Description | Preclinical studies | Phase I | Phase II | Phase III | Marketed |
Pharmaceutical programmes |
|||||||
| Alzheimer’s disease | Orally active, neurotrophic factor inducer |
50% |
|||||
| Parkinson's Disease | Orally active, neurotrophic factor inducer |
45% |
|||||
| ALS | Orally active, neurotrophic factor inducer |
40% Orphan |
|||||
| Asthma & COPD | TRPV1-modulator. Anti-inflammatory and airway relaxant and prevents airways remodelling |
20% |
|||||
| Age memory impairment | Improves cerebral blood flow and memory |
14% |
|||||
Functional food programmes |
|||||||
| Canine skin health | Natural, three plant product for canine skin health |
100% |
|||||
| Weight management | Reduces calorific intake |
60% |
|||||